Home
Vidar M. Steen's picture

Vidar M. Steen

Professor, Professor of Molecular Medicine
  • E-mailVidar.Steen@uib.no
  • Phone+47 55 97 53 27
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2020. The genetic architecture of the human cerebral cortex. Science.
  • Show author(s) 2020. The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications. 14 pages.
  • Show author(s) 2020. Runaway multi-allelic copy number variation at the α-defensin locus in African and Asian populations. Scientific Reports. 1-8.
  • Show author(s) 2020. Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults. Nature Communications.
  • Show author(s) 2020. Genetic control of variability in subcortical and intracranial volumes. Molecular Psychiatry. 1-8.
  • Show author(s) 2020. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial. The Lancet Psychiatry. 945-954.
  • Show author(s) 2019. Pleiotropic meta-analysis of cognition, education, and schizophrenia differentiates roles of early neurodevelopmental and adult synaptic pathways. American Journal of Human Genetics. 334-350.
  • Show author(s) 2019. Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study. Neuropsychopharmacology. 1-9.
  • Show author(s) 2019. Association of copy number variation of the 15q11.2 BP1-BP2 region with cortical and subcortical morphology and cognition. JAMA psychiatry. 11 pages.
  • Show author(s) 2018. Williams Syndrome neuroanatomical score associates with GTF2IRD1 in large-scale magnetic resonance imaging cohorts: A proof of concept for multivariate endophenotypes. Translational Psychiatry. 1-8.
  • Show author(s) 2018. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. Nature Communications. 1-16.
  • Show author(s) 2018. Recently evolved human-specific methylated regions are enriched in schizophrenia signals. BMC Evolutionary Biology. 1-11.
  • Show author(s) 2018. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nature Genetics. 912-919.
  • Show author(s) 2018. Expression of TCN1 in Blood is Negatively Associated with Verbal Declarative Memory Performance. Scientific Reports. 1-11.
  • Show author(s) 2018. Exploring the Wnt signaling pathway in schizophrenia and bipolar disorder. Translational Psychiatry. 1-10.
  • Show author(s) 2018. Comparison of three variant callers for human whole genome sequencing. Scientific Reports. 1-6.
  • Show author(s) 2018. Attenuated Notch signaling in schizophrenia and bipolar disorder. Scientific Reports. 1-8.
  • Show author(s) 2018. Associations between C-reactive protein levels and cognition during the first 6 months after acute psychosis. Acta Neuropsychiatrica. 1-10.
  • Show author(s) 2018. Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders. European Archives of Psychiatry and Clinical Neuroscience. 795-802.
  • Show author(s) 2018. Association between olanzapine treatment and brain cortical thickness and gray/white matter contrast is moderated by cholesterol in psychotic disorders. Psychiatry Research : Neuroimaging. 55-63.
  • Show author(s) 2018. Analysis of shared heritability in common disorders of the brain. Science. 15 pages.
  • Show author(s) 2018. A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome. European Journal of Human Genetics.
  • Show author(s) 2017. Subchronic olanzapine exposure leads to increased expression of myelination-related genes in rat fronto-medial cortex. Translational Psychiatry.
  • Show author(s) 2017. Novel genetic loci associated with hippocampal volume. Nature Communications. 1-12.
  • Show author(s) 2017. Large-scale cognitive GWAS meta-analysis reveals tissue-specific neural expression and potential nootropic drug targets. Cell reports. 2597-2613.
  • Show author(s) 2017. Identification of gene loci that overlap between schizophrenia and educational attainment. Schizophrenia Bulletin. 654-664.
  • Show author(s) 2017. GWAS meta-analysis reveals novel loci and genetic correlates for general cognitive function: a report form the COGENT consortium. Molecular Psychiatry. 336-345.
  • Show author(s) 2017. Duplicated enhancer region increases expression of CTSB and segregates with keratolytic winter erythema in South African and Norwegian families. American Journal of Human Genetics. 737-750.
  • Show author(s) 2017. BRCA testing by single-molecule molecular inversion probes. Clinical Chemistry. 503-512.
  • Show author(s) 2017. Analysis of the joint effect of SNPs to identify independent loci and allelic heterogeneity in schizophrenia GWAS data. Translational Psychiatry.
  • Show author(s) 2017. A genome-wide association study of anorexia nervosa suggests a risk locus implicated in dysregulated leptin signaling. Scientific Reports. 1-9.
  • Show author(s) 2017. A genetic association study of CSMD1 and CSMD2 with cognitive function. Brain, behavior, and immunity. 209-216.
  • Show author(s) 2016. The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. BMC Psychiatry.
  • Show author(s) 2016. RareVariantVis: New tool for visualization of causative variants in rare monogenic disorders using whole genome sequencing data. Bioinformatics. 3018-3020.
  • Show author(s) 2016. Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience. 1569-1582.
  • Show author(s) 2016. Genome-wide autozygosity is associated with lower general cognitive ability. Molecular Psychiatry. 837-843.
  • Show author(s) 2016. Genetics of structural connectivity and information processing in the brain. Brain Structure and Function. 4643-4661.
  • Show author(s) 2016. Genetic evidence for a role of the SREBP transcription system and lipid biosynthesis in schizophrenia and antipsychotic treatment. European Neuropsychopharmacology. 589-598.
  • Show author(s) 2016. Conservation of Distinct Genetically-Mediated Human Cortical Pattern. PLoS Genetics. 18 pages.
  • Show author(s) 2016. Circadian clock gene variants and insomnia, sleepiness, and shift work disorder. Sleep and Biological Rhythms. 55-62.
  • Show author(s) 2016. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. European Journal of Human Genetics. 881-888.
  • Show author(s) 2015. Transcriptional, post-transcriptional and chromatin-associated regulation of pri-miRNAs, pre-miRNAs and moRNAs. Nucleic Acids Research (NAR). 3070-3081.
  • Show author(s) 2015. Syndromic X-linked intellectual disability segregating with a missense variant in RLIM. European Journal of Human Genetics. 1652-1656.
  • Show author(s) 2015. Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain. European Neuropsychopharmacology. 923-932.
  • Show author(s) 2015. MicroRNAs enrichment in GWAS of complex human phenotypes. BMC Genomics.
  • Show author(s) 2015. Large-scale genomics unveil polygenic architecture of human cortical surface area. Nature Communications.
  • Show author(s) 2015. Independent evidence for an association between general cognitive ability and a genetic locus for educational attainment. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 363-373.
  • Show author(s) 2015. Incident users of antipsychotic agents and future use of cholesterol-lowering drugs: An observational, pharmacoepidemiologic study. Journal of Clinical Psychiatry. e111-e116.
  • Show author(s) 2015. Genetic contributions to variation in general cognitive function: a meta-analysis of genome-wide association studies in the CHARGE consortium (N=53 949). Molecular Psychiatry. 183-192.
  • Show author(s) 2015. Genetic basis of a cognitive complexity metric. PLOS ONE.
  • Show author(s) 2015. Common variants in the ARC gene are not associated with cognitive abilities. Brain and Behavior. 8 pages.
  • Show author(s) 2015. Common genetic variants influence human subcortical brain structures. Nature. 224-229.
  • Show author(s) 2015. B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability. Journal of Clinical Investigation. 3051-3062.
  • Show author(s) 2015. Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine. Journal of Psychopharmacology. 1280-1289.
  • Show author(s) 2014. The ENIGMA Consortium: Large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior. 153-182.
  • Show author(s) 2014. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. International Journal of Neuropsychopharmacology. 91-104.
  • Show author(s) 2014. Lack of association of the rs1344706 ZNF804A variant with cognitive functions and DTI indices of white matter microstructure in two independent healthy populations. Psychiatry Research : Neuroimaging. 60-66.
  • Show author(s) 2014. Human cognitive ability is influenced by genetic variation in components of postsynaptic signalling complexes assembled by NMDA receptors and MAGUK proteins. Translational Psychiatry.
  • Show author(s) 2014. Genetic architecture of cognitive traits. Scandinavian Journal of Psychology. 255-262.
  • Show author(s) 2014. GWAS-based pathway analysis differentiates between fluid and crystallized intelligence. Genes, Brain and Behavior.
  • Show author(s) 2014. A genome-wide association study of anorexia nervosa. Molecular Psychiatry. 1085-1094.
  • Show author(s) 2013. Neuropsychological deficits in mice depleted of the schizophrenia susceptibility gene CSMD1. PLOS ONE. 10 pages.
  • Show author(s) 2013. Gain-of-function mutations in the mechanically activated ion channel PIEZO2 cause a subtype of Distal Arthrogryposis. Proceedings of the National Academy of Sciences of the United States of America. 4667-4672.
  • Show author(s) 2013. Antipsychotic-induced increase in lipid biosynthesis: activation through inhibition? Journal of Lipid Research.
  • Show author(s) 2013. A genetic deconstruction of neurocognitive traits in schizophrenia and bipolar disorder. PLOS ONE. 9 pages.
  • Show author(s) 2012. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. International Journal of Neuropsychopharmacology. 163-179.
  • Show author(s) 2012. Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment. PLOS ONE. 11 pages.
  • Show author(s) 2012. Linkage-disequilibrium-based binning affects the interpretation of GWASs. American Journal of Human Genetics. 727-733.
  • Show author(s) 2012. Imaging and cognitive genetics: the Norwegian Cognitive NeuroGenetics Sample. Twin Research and Human Genetics. 442-452.
  • Show author(s) 2012. Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics. 552-561.
  • Show author(s) 2012. Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern. Sarcoma. 12 pages.
  • Show author(s) 2012. Gene-based analysis of regionally enriched cortical genes in GWAS data sets of cognitive traits and psychiatric disorders. PLOS ONE. 14 pages.
  • Show author(s) 2012. DCLK1 variants are associated across schizophrenia and attention deficit/hyperactivity disorder. PLOS ONE. 12 pages.
  • Show author(s) 2012. An actigraphic validation study of seven morningness-eveningness inventories. European Psychologist. 222-230.
  • Show author(s) 2012. Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology. 783-794.
  • Show author(s) 2011. The Complement Control-Related Genes CSMD1 and CSMD2 Associate to Schizophrenia. Biological Psychiatry. 35-42.
  • Show author(s) 2011. Olanzapine-induced hyperphagia and weight gain associate with crexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLOS ONE. 9 pages.
  • Show author(s) 2011. Lithium differentially affects clock gene expression in serum-shocked NIH-3T3 cells. Journal of Psychopharmacology. 924-933.
  • Show author(s) 2011. Gene expression in the rat brain: High similarity but unique differences between frontomedial-, temporal- and occipital cortex. BMC Neuroscience. 14 pages.
  • Show author(s) 2011. Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. Pharmacopsychiatry. 15-20.
  • Show author(s) 2010. Usefulness of factor V Leiden mutation testing in clinical practice. European Journal of Human Genetics. 862-866.
  • Show author(s) 2010. Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. Brain Pathology. 720-729.
  • Show author(s) 2010. Switch from stress response to homeobox transcription factors in adipose tissue after profound fat loss. PLOS ONE. 12 pages.
  • Show author(s) 2010. Neurogenetic effects on cognition in aging brains: A window of opportunity for intervention? Frontiers in Aging Neuroscience. 15 pages.
  • Show author(s) 2010. Mutations in ABHD12 Cause the Neurodegenerative Disease PHARC: An Inborn Error of Endocannabinoid Metabolism. American Journal of Human Genetics. 410-417.
  • Show author(s) 2010. Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. Journal of Psychiatric Research. 748-753.
  • Show author(s) 2010. Er formakogenetisk CYP2D6-testing nyttig? Tidsskrift for Den norske legeforening. 2224-2228.
  • Show author(s) 2010. Er farmakogenetisk CYP2D6-testing nyttig? Tidsskrift for Den norske legeforening. 2224-2228.
  • Show author(s) 2010. Association Study of PDE48 gene variants in Scandinavian schizophrenia and bipolar disorder multicenter case-control samples. American Journal of Medical Genetics. 86-96.
  • Show author(s) 2008. Polymorphisms in SREBF1 and SREBF2, two antipsychotic-activated transcription factors controlling cellular lipogenesis, are associated with schizophrenia in German and Scandinavian samples. Molecular Psychiatry.
  • Show author(s) 2008. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. International Journal of Neuropsychopharmacology. 679-684.
  • Show author(s) 2008. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. International Journal of Neuropsychopharmacology. 679-684.
  • Show author(s) 2008. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Annals of Oncology. 56-61.
  • Show author(s) 2008. Auditory hallucinations in schizophrenia: the role of cognitive, brain structural and genetic disturbances in the left temporal lobe. Frontiers in Human Neuroscience. 10 pages.
  • Show author(s) 2008. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: pertubation of SREBP-controlled lipogenesis in drug-realted metabolic adverse effects? Molecular Psychiatry. 308-317.
  • Show author(s) 2008. Association Analysis of Schizophrenia on 18 Genes Involved in Neuronal Migration: MDGA1 as a New Susceptibility Gene. American Journal of Medical Genetics. 1089-1100.
  • Show author(s) 2008. Array-CGH fine mapping of minor and cryptic HR-CGH detected genomic imbalances in 80 out of 590 patients with abnormal development. European Journal of Human Genetics. 1318-1328.
  • Show author(s) 2008. A possible association between schizophrenia and GRIK3 polymorphisms in a multicenter sample of Scandinavian origin (SCOPE). Schizophrenia Research.
  • Show author(s) 2007. Synaptic activity-induced global gene expression patterns in the dentate gyrus of adult behaving rats: Induction of immunity-linked genes. Neuroscience. 925-936.
  • Show author(s) 2007. Hyperoxia retards growth and induces apoptosis and loss of glands and blood vessels in DMBA-induced rat mammary tumors. BMC Cancer. 10 pages.
  • Show author(s) 2007. Gene expression profiles in rat brain disclose CNS signature genes and regional patterns of functional specialisation. BMC Genomics.
  • Show author(s) 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • Show author(s) 2007. Associations between cod liver oil use and symptoms of depression: The Hordaland Health Study. Journal of Affective Disorders. 245-249.
  • Show author(s) 2007. A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment. Breast Cancer Research and Treatment. S144-S144.
  • Show author(s) 2006. SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: Relevance for metabolic side-effects? Molecular and Cellular Biochemistry. 167-173.
  • Show author(s) 2006. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: The Hordaland Health Study. Journal of Clinical Psychiatry. 1974-1982.
  • Show author(s) 2006. Identification of genes co-upregulated with Arc during BDNF-induced long-term potentiation in adult rat dentate gyrus in vivo. European Journal of Neuroscience. 1501-1511.
  • Show author(s) 2006. Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. European Respiratory Journal. 682-688.
  • Show author(s) 2006. Farmakogenetikk og skreddersydd behandling ved schizofreni. Tidsskrift for Den norske legeforening. 2400-2402.
  • Show author(s) 2006. Farmakogenetikk og skreddersydd behandling ved schizofreni. Tidsskrift for Den norske legeforening. 2400-2402.
  • Show author(s) 2006. Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: Marked differences between various antipsychotic drugs. BMC Neuroscience.
  • Show author(s) 2006. Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neuroscience Letters. 185-190.
  • Show author(s) 2005. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects. European Journal of Clinical Pharmacology. 499-506.
  • Show author(s) 2005. The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects. European Journal of Clinical Pharmacology. 499-506.
  • Show author(s) 2005. Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? The Pharmacogenomics Journal. 298-304.
  • Show author(s) 2004. The ser9gly SNP in the dopamine D-3 receptor causes a shift from cAMP related to PGE(2) related signal transduction mechanisms in transfected CHO cells. Journal of Medical Genetics. 867-871.
  • Show author(s) 2004. Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder. Molecular Psychiatry. 621-629.
  • Show author(s) 2004. Evaluation of five different cDNA labeling methods for microarrays using spike controls. BMC Biotechnology. 5 pages.
  • Show author(s) 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. Journal of Clinical Psychiatry. 1228-1234.
  • Show author(s) 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: Infant exposure, clinical symptoms and cytochrome P450 genotypes. Journal of Clinical Psychiatry. 1228-1234.
  • Show author(s) 2003. Examination of IMPA1- and IMPA2 genes in manic-depressive patients: Association between IMPA2 promoter polymorphisms and bipolar disorder. Molecular Psychiatry. Epub-23Dec2003.
  • Show author(s) 2003. Evaluation of of five different cDNA labeling methods for microarrays using spike controls. BMC Biotechnology.
  • Show author(s) 2003. Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics (London). 383-388.
  • Show author(s) 2003. Association between blood carisoprodol/meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: Decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics (London). 383-388.
  • Show author(s) 2003. Association between blood carisoprodol/meprobamate concentration ratios and CYP2C19 genotype in carisoprodol drugged drivers: Decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics (London). 383-388.
  • Show author(s) 2002. Schizofreni og molekylærgenetikk. Tidsskrift for Den norske legeforening. 2118-2122.
  • Show author(s) 2002. Pharmacogenetics of tardive dyskinesia: Combined analysis of 780 patients supports association with dopamine D3 receptor gene ser9gly polymorphism. Neuropsychopharmacology. 105-119.
  • Show author(s) 2002. Does inositol signalling have a role in disease susceptibility and drug treatment of bipolar disorder? Bipolar Disorders. 53-55.
  • Show author(s) 2001. The phospholipase C-gamma 1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatric Genetics. 41-43.
  • Show author(s) 2001. Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients. Molecular Psychiatry. 6-7.
  • Show author(s) 2001. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics (London). 45-55.
  • Show author(s) 2001. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics (London). 45-55.
  • Show author(s) 2001. Characterization of two genes, Impa1 and Impa2 encoding mouse myo-inositol monophosphatases. Gene. 285-291.
  • Show author(s) 2000. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. International Journal of Neuropsychopharmacology. 61-65.
  • Show author(s) 2000. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. International Journal of Neuropsychopharmacology. 61-65.
  • Show author(s) 2000. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. International Journal of Neuropsychopharmacology.
  • Show author(s) 2000. CYP2D6-gentest- ny rutineanalyse for identifisering av langsomme og ultraraske legemiddelomsettere. Norsk Farmaceutisk Tidsskrift. 14-15.
  • Show author(s) 2000. A human myoinositol monophosphatase gene (IMPA2) localized in a susc eptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Molecular Psychiatry.
  • Show author(s) 2000. A human myoinositol monophosphatase gene (IMPA2) localized in a susc eptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Molecular Psychiatry. 172-180.
  • Show author(s) 2000. A human myoinositol monophosphatase gene (IMPA2) localized in a susc eptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Molecular Psychiatry. 172-180.
  • Show author(s) 1999. Genomic structure and sequence analysis of a human inositol polyphosphate 1-phosphatase gene (INPP1). Pharmacogenetics (London). 517-528.
  • Show author(s) 1998. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illn. Pharmacogenetics (London). 259-268.
  • Show author(s) 1998. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illn. Pharmacogenetics (London). 259-268.
  • Show author(s) 1997. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in szhizophrenic patients. Psychopharmacology. 174-179.
  • Show author(s) 1997. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizofrenic patients. Psychopharmacology. 174-179.
  • Show author(s) 1997. Genomic structure and chromosomal localization of a human myo-inositol monophosphatase gene (IMPA). Genomics. 113-122.
  • Show author(s) 1997. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Molecular Psychiatry. 139-145.
  • Show author(s) 1997. Characterization of the 16+9 kb and 30+9 kb CYP2D6 Xbal haplotypes. Pharmacogenetics (London). 149-152.
  • Show author(s) 1996. Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Letters. 30-34.
  • Show author(s) 1996. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness. Pharmacogenetics (London). 113-116.
  • Show author(s) 1996. Lack of genetic variation in the coding region of the myo-inositol monophosphatase gene in lithium-treated patients with manic depressive illness. Pharmacogenetics (London). 113-116.
  • Show author(s) 1996. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics (London). 319-328.
  • Show author(s) 1996. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics (London). 319-328.
  • Show author(s) 1996. CYP2D6 multiallelism. Methods in Enzymology. 199-210.
  • Show author(s) 1996. A retroviral element in the human CYP2D gene cluster. Pharmacogenetics (London). 375-377.
  • Show author(s) 1995. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of the human cytochrome P450 CYP2D6 gene. Hum Molecul Genet. 2251-2257.
  • Show author(s) 1995. Detection of the poor metabolizer-associated CYP2D6(D) gene detection allele by long-PCR technology. Pharmacogenetics (London). 215-223.
  • Show author(s) 1995. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics (London). 215-223.
  • Show author(s) 1993. The platelet-stimulating effect of adrenaline through _a%c-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce platelet activation in vitro. Thrombosis and Haemostasis. 506-513.
  • Show author(s) 1991. Stimulation of human platelets with low concentrations of thrombin: Evidence for equimolecular formation of inositol triphosphate and phosphatidic acid. International journal of biochemistry. 305-310.
Academic lecture
  • Show author(s) 2012. Integrative genomics links homeobox transcription factors to intra-abdominal obesity.
  • Show author(s) 2004. Antipsychotic-induced changes in global gene expression: Demonstration of novel mechanisms of drug action based on clustering and verification of differential expressed genes.
  • Show author(s) 2003. Candidate genes in bipolar disorder: Implications for treatment.
  • Show author(s) 2001. The role of genetic variation in lithium treatment of maniac-depressive illness.
  • Show author(s) 2001. Inositol monophosphatase, a candidate gene for bipolar disorder?
  • Show author(s) 2001. IMPA1 and IMPA2 - Candidate genes for disease susceptibility and variation in drug response in lithium-treated bipolar disorder.
  • Show author(s) 2001. Clock genes: Regulation and gene expression.
  • Show author(s) 2000. The role of gene mutations of the inositol phospholipid signaling system in lithium-treated bipolar disorder.
  • Show author(s) 2000. The role of gene mutations of the inositol phospholipid signaling system in lithium-treated bipolar disorder.
  • Show author(s) 2000. The role of gene mutations of the inositol phospholipid signaling system in lithium-trated bipolar disorder.
  • Show author(s) 1999. Searching for genetic variations in inositol monophosphatase genes in lithium-treated manic-depressive patients.
  • Show author(s) 1999. Examination of a phospholipase C gamma-1 dinucleotide repeat polymorphism in Norwegian Lithium-treated bipolar patients.
  • Show author(s) 1999. Allele frequency and genotype distribution of a novel structural polymorphism in the alpha-2B-adrenoceptor gene in bipolar patients and normal control individuals.
  • Show author(s) 1999. Allele frequency and genotype distribution of a novel structural polymorphism in the (2B-adrenergic receptor in bipolar patients and normal control individuals.
  • Show author(s) 1999. A role of the human inositol polyphosphate 1-phosphatase gene (INPP1) in lithium-treated bipolar disorder?
  • Show author(s) 1998. Homozygosity for the Ser9Gly variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients: a follow-up study.
  • Show author(s) 1998. Genomic structure and sequence analysis of a human inositol polyphosphate 1-phosphatase gene (INPP1).
  • Show author(s) 1998. Genomic characterization of genes encoding human myo-inositol monophosphatase enzymes.
  • Show author(s) 1998. Gene mutations of the phosphatidylinositol signaking system in lithium-treated manic-depressive patients.
  • Show author(s) 1997. Screening for genetic factors which may be involved in the mechanism of action of lithium in manic depressiv illness.
  • Show author(s) 1997. Gene mutations in the phosphatidylinositol system in bipolar patients.
  • Show author(s) 1997. Gene mutations in the phosphatidylinositol system in bipolar patients.
  • Show author(s) 1997. Gene mutations in the phosphatidylinositol system in bipolar patients.
  • Show author(s) 1996. Screening for genetic fractors which may be involved in the mechanism of action lithium in manic-depressive illness.
Abstract
  • Show author(s) 2010. Genetic characterisation of PHARC - a novel syndrome resembling Refsum's disease. Neuromuscular Disorders. 680-680.
  • Show author(s) 2010. Gene Expression Profile of Nuclear Receptors and Coregulators in Adipose Tissues in Morbid Obesity and after Profound Fat Loss. Endocrine reviews. 1 pages.
  • Show author(s) 2010. From stress response to developmental processes in abdominal subcutaneous adipose tissue after bariatric surgery. Endocrine journal. S429-S429.
  • Show author(s) 2010. Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism. European Journal of Cancer. 60-60.
  • Show author(s) 2008. Effect of clozapine on memory function in the hippocampal lesion model of schizophrenia. International Journal of Neuropsychopharmacology. 261-261.
  • Show author(s) 2008. Differential effects of antipsychotic drugs on ATP-binding cassette type A1 (ABCA1) and apolipoprotein E (ApoE) gene expression in cultured cells. International Journal of Neuropsychopharmacology. 259-259.
  • Show author(s) 2008. Antipsychotic-induced activation of cellular lipid biosynthesis: Molecular, genetic and clinical evidence for a new mechanism of metabolic drug action. International Journal of Neuropsychopharmacology. 31-31.
  • Show author(s) 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • Show author(s) 2007. Variations in side effects of antipsychotic drugs: Focus on possible mechanisms. Nordic Journal of Psychiatry. 493-493.
  • Show author(s) 2007. Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Nordic Journal of Psychiatry. 501-501.
  • Show author(s) 2007. Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients. Breast. S15-S15.
  • Show author(s) 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • Show author(s) 2006. Lipogenic effects of antidepressant drugs: Transcriptional stimulation of cellular lipid biosynthesis is a potential marker of drug-induced metabolic side-effects. Nordic Journal of Psychiatry. 336-336.
  • Show author(s) 2006. Antipsychotic and antidepressive drugs regulate the expression of apolipoprotein E. Nordic Journal of Psychiatry. 338-338.
  • Show author(s) 2005. Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. Breast Cancer Research and Treatment. S236-S237.
Academic literature review
  • Show author(s) 2019. Constructing the immune signature of schizophrenia for clinical use and research; an integrative review translating descriptives into diagnostics. Frontiers in Psychiatry. 1-16.

More information in national current research information system (CRIStin)